Oral topotecan: bioavailability and effect of food co-administration

被引:54
作者
Herben, VMM
Rosing, H
Huinink, WWT
van Zomeren, DM
Batchelor, D
Doyle, E
Beusenberg, FD
Beijnen, JH
Schellens, JHM
机构
[1] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[3] SmithKline Beecham Pharmaceut, Dept Drug Metab & Pharmacokinet, Welwyn Garden City, Herts, England
[4] SmithKline Beecham Farma, Rijswijk, Netherlands
关键词
topotecan; oral; bioavailability; food;
D O I
10.1038/sj.bjc.6690532
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aims of the study were twofold: (1) to evaluate the effect of food on the relative oral bioavailability of topotecan gelatin capsules in patients with solid tumours, and (2) to determine the absolute bioavailability of oral topotecan with reference to the intravenous (i.v.) formulation. The study had a randomized two-period cross-over design. On day 1 of the first treatment course patients were administered 2.3 mg m(-2) day(-1) of oral topotecan with or without a high-fat breakfast. They crossed over to receive the alternate regimen on day 2. In the second course (3 weeks later) fasted patients received topotecan orally (2.3 mg m(-2) day(-1)) or i.v. (1.5 mg m(-3) day). They crossed over to receive the alternate regimen on day 2. On days 3-5 of both treatment courses patients received oral topotecan, Plasma pharmacokinetics were performed on days 1 and 2 of the first and second course using a high-performance liquid chromatographic assay. Eighteen patients were enrolled in the study. The ratio of the area under the curve to infinity during fasted and high-fat treatment was 0.93 +/- 0.23 (90% confidence interval (CI) 0.83-1.03). Maximal plasma concentrations of topotecan were similar after ingestion of the capsules with (10.6 +/- 4.4 ng ml(-1)) or without food (9.2 +/- 4.1 ng ml(-1)) (P = 0.130). The lime needed to reach maximal plasma levels was significantly prolonged after food intake (median 3.1 h, range 2.8-6.1) compared to fasted conditions (2.0 h, range 1.1-8.1) (P = 0.013). The absolute bioavailability of topotecan averaged 42 +/- 13% (90% CI 37- 47%). The apparent terminal half-life was significantly longer after administration of oral topotecan (3.9 +/- 1.0 h) than after i.v. administration (2.7 +/- 0.4 h) (P < 0.001). Topotecan demonstrates suitable bioavailability for oral treatment. Go-administration of the topotecan gelatin capsules with a high-fat breakfast leads to a small decrease in absorption rate but does not affect the extent of absorption.
引用
收藏
页码:1380 / 1386
页数:7
相关论文
共 20 条
[1]   COMPREHENSIVE CRITERIA FOR ASSESSING THERAPY-INDUCED TOXICITY [J].
AJANI, JA ;
WELCH, SR ;
RABER, MN ;
FIELDS, WS ;
KRAKOFF, IH .
CANCER INVESTIGATION, 1990, 8 (02) :147-159
[2]   ACTIVITY OF TOPOTECAN, A NEW TOPOISOMERASE-I INHIBITOR, AGAINST HUMAN TUMOR COLONY-FORMING-UNITS INVITRO [J].
BURRIS, HA ;
HANAUSKE, AR ;
JOHNSON, RK ;
MARSHALL, MH ;
KUHN, JG ;
HILSENBECK, SG ;
VONHOFF, DD .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (23) :1816-1820
[3]  
*COMM PROPR MED PR, 1992, NOT GUID INV BIOAV B
[4]   Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors [J].
Creemers, GJ ;
Gerrits, CJH ;
Eckardt, JR ;
Schellens, JHM ;
Burris, HA ;
Planting, AST ;
Rodriguez, GI ;
Loos, WJ ;
Hudson, I ;
Broom, C ;
Verweij, J ;
VonHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :1087-1093
[5]  
DAVIES BE, 1995, EUR J CANCER A S5, V31, pS28
[6]  
ECKARDT J, 1995, EUR J CANCER, V31, pS193
[7]  
GERRITS CJH, 1998, EUR J CANCER, V7, P34
[8]   Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide [J].
Herben, VMM ;
Huinink, WWT ;
Dubbelman, AC ;
Mandjes, IAM ;
Groot, Y ;
vanZomeren, DMV ;
Beijnen, JH .
BRITISH JOURNAL OF CANCER, 1997, 76 (11) :1500-1508
[9]   MODIFICATION OF THE HYDROXY LACTONE RING OF CAMPTOTHECIN - INHIBITION OF MAMMALIAN TOPOISOMERASE-I AND BIOLOGICAL-ACTIVITY [J].
HERTZBERG, RP ;
CARANFA, MJ ;
HOLDEN, KG ;
JAKAS, DR ;
GALLAGHER, G ;
MATTERN, MR ;
MONG, SM ;
BARTUS, JO ;
JOHNSON, RK ;
KINGSBURY, WD .
JOURNAL OF MEDICINAL CHEMISTRY, 1989, 32 (03) :715-720
[10]  
HOUGHTON PJ, 1995, CANCER CHEMOTH PHARM, V36, P393